Volume 27, Number 9—September 2021
Research
Genomic Epidemiology of Azithromycin-Nonsusceptible Neisseria gonorrhoeae, Argentina, 2005–2019
Table 2
Antimicrobial susceptibility of 96 azithromycin-resistant Neisseria gonorrhoeae isolates, Argentina, January 2005–November 2019*
Antimicrobial drug | Azithromycin MICs, μg/mL (no. isolates) |
||||||
---|---|---|---|---|---|---|---|
2–16 (91) |
>256 (5) |
||||||
MIC50 | MIC90 | Range | Resistance, % | MIC | Resistance, % | ||
Ciprofloxacin | 0.004 | 16 | 0.001–32 | 28.6 | 0.002–4 | 20 | |
Tetracycline | 1 | 2 | 0.125–4 | 25.3 | 0.5–2 | 20 | |
Benzylpenicillin | 1 | 2 | 0.25–8 | 14.3 | 0.5–1 | 0 | |
Ceftriaxone | 0.004 | 0.03 | 0.002–0.06 | 0 | 0.004–0.016 | 0 | |
Cefixime | 0.016 | 0.03 | 0.004–0.125 | 0 | 0.008–0.03 | 0 | |
Spectinomycin | 32 | 32 | 16–32 | 0 | 32 | 0 | |
Gentamicin | 8 | 8 | 4–16 | 0 | 8–16 | 0 |
*MIC50, MIC for 50% of isolates; MIC90, MIC for 90% of isolates.
1Members of this group are listed at the end of the article.
Page created: July 01, 2021
Page updated: August 17, 2021
Page reviewed: August 17, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.